JP2006063074A5 - - Google Patents

Download PDF

Info

Publication number
JP2006063074A5
JP2006063074A5 JP2005219763A JP2005219763A JP2006063074A5 JP 2006063074 A5 JP2006063074 A5 JP 2006063074A5 JP 2005219763 A JP2005219763 A JP 2005219763A JP 2005219763 A JP2005219763 A JP 2005219763A JP 2006063074 A5 JP2006063074 A5 JP 2006063074A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
group
composition according
hydroxymethyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005219763A
Other languages
Japanese (ja)
Other versions
JP2006063074A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2005219763A priority Critical patent/JP2006063074A/en
Priority claimed from JP2005219763A external-priority patent/JP2006063074A/en
Publication of JP2006063074A publication Critical patent/JP2006063074A/en
Publication of JP2006063074A5 publication Critical patent/JP2006063074A5/ja
Pending legal-status Critical Current

Links

Claims (49)

下記一般式(I)

[式中、Aは下記一般式(A1)、(A2)又は(A3)

を示し、R1及びR２はそれぞれ同一若しくは異なって、C1-6アルキル基、ヒドロキシメチル基、C1-6アルコキシメチル基又はC1-6ハロアルキル基を示し、R3、R4、R5及びR6はそれぞれ同一若しくは異なって、C1-6アルキル基、C1-6アルコキシ基、C1-6ヒドロキシアルキル基、C1-6ハロアルキル基、アミノ基(該アミノ基はC1-6アルキル基又はC1-6ヒドロキシアルキル基で1又は2個置換されていてもよい) 、水酸基、水素原子又はハロゲン原子を示し、R7はC1-6アルキル基、C1-6アルコキシ基、C1-6ヒドロキシアルキル基、C1-6ハロアルキル基、水酸基又は水素原子を示し、nは1又は2の整数を示す。] で表わされる化合物又はその薬理上許容される塩若しくはエステルから選ばれるα‐アミラーゼ阻害剤と、インスリン感受性増強剤、インスリン分泌促進剤、ビグアナイド剤、インスリン製剤及びDPP-IV阻害剤から選ばれる少なくとも一種の薬剤とを組み合わせてなる医薬組成物。 The following general formula (I)

[Wherein A represents the following general formula (A1), (A2) or (A3)

R 1 and R 2 are the same or different and each represents a C 1-6 alkyl group, a hydroxymethyl group, a C 1-6 alkoxymethyl group or a C 1-6 haloalkyl group, and R 3 , R 4 , R 5 and R 6 are the same or different and each represents a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 hydroxyalkyl group, a C1-6 haloalkyl group, an amino group (the amino group is a C1-6 alkyl group or a C1-6 hydroxy group). 1 or 2 may be substituted with an alkyl group), a hydroxyl group, a hydrogen atom or a halogen atom, R 7 is a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 hydroxyalkyl group, C1-6 A haloalkyl group, a hydroxyl group or a hydrogen atom; n represents an integer of 1 or 2; An α-amylase inhibitor selected from the compounds represented by the formula (I) or a pharmacologically acceptable salt or ester thereof, and at least selected from an insulin sensitivity enhancer, an insulin secretagogue, a biguanide, an insulin preparation, and a DPP-IV inhibitor. A pharmaceutical composition comprising a combination of a kind of drugs. 下記一般式(I)

[式中、Aは下記一般式(A1)、(A2)又は(A3)

を示し、R1及びR２はそれぞれ同一若しくは異なって、C1-6アルキル基、ヒドロキシメチル基、C1-6アルコキシメチル基又はC1-6ハロアルキル基を示し、R3、R4、R5及びR6はそれぞれ同一若しくは異なって、C1-6アルキル基、C1-6アルコキシ基、C1-6ヒドロキシアルキル基、C1-6ハロアルキル基、アミノ基(該アミノ基はC1-6アルキル基又はC1-6ヒドロキシアルキル基で1又は2個置換されていてもよい) 、水酸基、水素原子又はハロゲン原子を示し、R7はC1-6アルキル基、C1-6アルコキシ基、C1-6ヒドロキシアルキル基、C1-6ハロアルキル基、水酸基又は水素原子を示し、nは1又は2の整数を示す。] で表わされる化合物又はその薬理上許容される塩若しくはエステルから選ばれるα‐アミラーゼ阻害剤と、インスリン感受性増強剤、インスリン分泌促進剤、ビグアナイド剤及びインスリン製剤から選ばれる薬剤の少なくとも一種とを組み合わせてなる医薬組成物。 The following general formula (I)

[Wherein A represents the following general formula (A1), (A2) or (A3)

R 1 and R 2 are the same or different and each represents a C 1-6 alkyl group, a hydroxymethyl group, a C 1-6 alkoxymethyl group or a C 1-6 haloalkyl group, and R 3 , R 4 , R 5 and R 6 are the same or different and each represents a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 hydroxyalkyl group, a C1-6 haloalkyl group, an amino group (the amino group is a C1-6 alkyl group or a C1-6 hydroxy group). 1 or 2 may be substituted with an alkyl group), a hydroxyl group, a hydrogen atom or a halogen atom, R 7 is a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 hydroxyalkyl group, C1-6 A haloalkyl group, a hydroxyl group or a hydrogen atom; n represents an integer of 1 or 2; Or a pharmacologically acceptable salt or ester thereof and an at least one drug selected from an insulin sensitivity enhancer, an insulin secretagogue, a biguanide, and an insulin preparation. A pharmaceutical composition. R1がC1-3アルキル基、ヒドロキシメチル基、C1-3アルコキシメチル基又はC1-3ハロアルキル基である請求項１又は２に記載の医薬組成物。 The pharmaceutical composition according to claim 1 or 2, wherein R 1 is a C1-3 alkyl group, a hydroxymethyl group, a C1-3 alkoxymethyl group or a C1-3 haloalkyl group. R1がメチル基又はヒドロキシメチル基である請求項１乃至３に記載の医薬組成物。 The pharmaceutical composition according to claims 1 to 3, wherein R 1 is a methyl group or a hydroxymethyl group. R２がヒドロキシメチル基又はC1-3ハロアルキル基である請求項１乃至４に記載の医薬組成物。 The pharmaceutical composition according to claims 1 to 4, wherein R 2 is a hydroxymethyl group or a C1-3 haloalkyl group. R２がヒドロキシメチル基である請求項１乃至５に記載の医薬組成物。 The pharmaceutical composition according to any one of claims 1 to 5, wherein R 2 is a hydroxymethyl group. Aが下記一般式(A1)

である請求項１乃至６に記載の医薬組成物。 A is the following general formula (A1)

The pharmaceutical composition according to any one of claims 1 to 6. R3、R4及びR5がそれぞれ同一若しくは異なって、ヒドロキシメチル基、水酸基又は水素原子である請求項７に記載の医薬組成物。 The pharmaceutical composition according to claim 7, wherein R 3 , R 4 and R 5 are the same or different and each is a hydroxymethyl group, a hydroxyl group or a hydrogen atom. R7が水素原子である請求項７又は８に記載の医薬組成物。 The pharmaceutical composition according to claim 7 or 8, wherein R 7 is a hydrogen atom. α‐アミラーゼ阻害剤とインスリン感受性増強剤とを組み合わせてなる請求項１に記載の医薬組成物。   The pharmaceutical composition according to claim 1, which comprises a combination of an α-amylase inhibitor and an insulin sensitivity enhancer. α‐アミラーゼ阻害剤とインスリン感受性増強剤とを組み合わせてなる、体重増加が抑制された、請求項１に記載の医薬組成物。   The pharmaceutical composition according to claim 1, wherein weight gain is suppressed, comprising a combination of an α-amylase inhibitor and an insulin sensitivity enhancer. α‐アミラーゼ阻害剤とインスリン感受性増強剤とを組み合わせてなる、心肥大が抑制された、請求項１に記載の医薬組成物。   The pharmaceutical composition according to claim 1, wherein cardiac hypertrophy is suppressed, comprising a combination of an α-amylase inhibitor and an insulin sensitivity enhancer. インスリン感受性増強剤がPPARγ活性化剤である、請求項１０乃至１２に記載の医薬組成物。   The pharmaceutical composition according to claim 10 to 12, wherein the insulin sensitivity enhancer is a PPARγ activator. インスリン感受性増強剤がピオグリタゾン、ロジグリタゾン、5-[4-(6-メトキシ-1-メチル-1H-ベンゾイミダゾール-2-イルメトキシ)ベンジル]チアゾリジン-2,4-ジオン又はその薬理上許容される塩である、請求項１０乃至１２に記載の医薬組成物。  Insulin sensitivity enhancer is pioglitazone, rosiglitazone, 5- [4- (6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy) benzyl] thiazolidine-2,4-dione or a pharmacologically acceptable salt thereof The pharmaceutical composition according to claim 10 to 12, wherein インスリン感受性増強剤がピオグリタゾン又はロジグリタゾンである、請求項１０乃至１２に記載の医薬組成物。   The pharmaceutical composition according to claim 10 to 12, wherein the insulin sensitivity enhancer is pioglitazone or rosiglitazone. インスリン感受性増強剤がピオグリタゾンである、請求項１０乃至１２に記載の医薬組成物。   The pharmaceutical composition according to claims 10 to 12, wherein the insulin sensitivity enhancer is pioglitazone. α‐アミラーゼ阻害剤とインスリン分泌促進剤とを組み合わせてなる請求項１に記載の医薬組成物。   The pharmaceutical composition according to claim 1, comprising an α-amylase inhibitor and an insulin secretagogue in combination. インスリン分泌促進剤がスルフォニル尿素剤又は速効型インスリン分泌促進剤である請求項１７に記載の医薬組成物。 The pharmaceutical composition according to claim 17 , wherein the insulin secretagogue is a sulfonylurea or a rapid-acting insulin secretagogue. インスリン分泌促進剤がグリベンクラミド、グリメピリド又はナテグリニドである請求項１７に記載の医薬組成物。 The pharmaceutical composition according to claim 17 , wherein the insulin secretagogue is glibenclamide, glimepiride or nateglinide. インスリン分泌促進剤がナテグリニドである請求項１７に記載の医薬組成物。 The pharmaceutical composition according to claim 17 , wherein the insulin secretagogue is nateglinide. α‐アミラーゼ阻害剤とビグアナイド剤とを組み合わせてなる請求項１に記載の医薬組成物。   The pharmaceutical composition according to claim 1, which comprises a combination of an α-amylase inhibitor and a biguanide agent. α‐アミラーゼ阻害剤とビグアナイド剤とを組み合わせてなる、乳酸値の上昇が抑制された、請求項１に記載の医薬組成物。   The pharmaceutical composition according to claim 1, wherein an increase in lactic acid level is suppressed by combining an α-amylase inhibitor and a biguanide agent. ビグアナイド剤がメトホルミン、フェンホルミン又はブホルミンである請求項２１又は２２に記載の医薬組成物。 The pharmaceutical composition according to claim 21 or 22 , wherein the biguanide is metformin, phenformin or buformin. ビグアナイド剤がメトホルミンである請求項２１又は２２に記載の医薬組成物。 The pharmaceutical composition according to claim 21 or 22 , wherein the biguanide is metformin. α‐アミラーゼ阻害剤とDPP-IV阻害剤とを組み合わせてなる請求項１に記載の医薬組成物。   The pharmaceutical composition according to claim 1, comprising an α-amylase inhibitor and a DPP-IV inhibitor in combination. DPP-IV阻害剤がMK-0431、LAF-237又はBMS-477118である請求項２５に記載の医薬組成物。 The pharmaceutical composition according to claim 25 , wherein the DPP-IV inhibitor is MK-0431, LAF-237 or BMS-477118. DPP-IV阻害剤がMK-0431である請求項２５に記載の医薬組成物。 The pharmaceutical composition according to claim 25 , wherein the DPP-IV inhibitor is MK-0431. 経口投与用である請求項１０乃至２７に記載の医薬組成物。 28. The pharmaceutical composition according to claim 10 to 27 , which is for oral administration. 配合剤として投与するための、請求項１０乃至２８に記載の医薬組成物。  29. A pharmaceutical composition according to claim 10 to 28 for administration as a combination. α‐アミラーゼ阻害剤とインスリン製剤とを組み合わせてなる請求項１に記載の医薬組成物。   The pharmaceutical composition according to claim 1, which comprises a combination of an α-amylase inhibitor and an insulin preparation. α‐アミラーゼ阻害剤とインスリン製剤とを組み合わせることにより、低血糖又は体重増加が低減された、請求項３０に記載の医薬組成物。The pharmaceutical composition according to claim 30, wherein hypoglycemia or weight gain is reduced by combining an α-amylase inhibitor and an insulin preparation. インスリン製剤が速効型インスリンである請求項３０又は３１に記載の医薬組成物。 The pharmaceutical composition according to claim 30 or 31 insulin preparation is fast-acting insulin. α‐アミラーゼ阻害剤が(2R,3R,4R)-4-ヒドロキシ-2-ヒドロキシメチル-ピロリジン-3-イル 4-O-(6-デオキシ-α-D-グルコピラノシル)-α-D-グルコピラノシド、(2R,3R,4R)-4-ヒドロキシ-2-ヒドロキシメチル-ピロリジン-3-イル 4-O-(6-デオキシ-β-D-グルコピラノシル)-α-D-グルコピラノシド、(2R,3R,4R)-4-ヒドロキシ-2-ヒドロキシメチル-ピロリジン-3-イル 4-O-β-D-グルコピラノシル-α-D-グルコピラノシド、(2R,3R,4R)-4-ヒドロキシ-2-ヒドロキシメチル-ピロリジン-3-イル 4-O-(6-フルオロ-6-デオキシ-β-D-グルコピラノシル)-D-グルコピラノシド又はその薬理上許容される塩若しくはエステルである請求項１乃至３２に記載の医薬組成物。 an α-amylase inhibitor is (2R, 3R, 4R) -4-hydroxy-2-hydroxymethyl-pyrrolidin-3-yl 4-O- (6-deoxy-α-D-glucopyranosyl) -α-D-glucopyranoside, (2R, 3R, 4R) -4-hydroxy-2-hydroxymethyl-pyrrolidin-3-yl 4-O- (6-deoxy-β-D-glucopyranosyl) -α-D-glucopyranoside, (2R, 3R, 4R ) -4-Hydroxy-2-hydroxymethyl-pyrrolidin-3-yl 4-O-β-D-glucopyranosyl-α-D-glucopyranoside, (2R, 3R, 4R) -4-hydroxy-2-hydroxymethyl-pyrrolidine The pharmaceutical composition according to any one of claims 1 to 32 , which is -3-yl 4-O- (6-fluoro-6-deoxy-β-D-glucopyranosyl) -D-glucopyranoside or a pharmacologically acceptable salt or ester thereof. . α‐アミラーゼ阻害剤が(2R,3R,4R)-4-ヒドロキシ-2-(ヒドロキシメチル)ピロリジン-3-イル 4-O-(6-デオキシ-α-D-グルコピラノシル)-α-D-グルコピラノシド、(2R,3R,4R)-4-ヒドロキシ-2-(ヒドロキシメチル)ピロリジン-3-イル 4-O-(6-デオキシ-β-D-グルコピラノシル)-α-D-グルコピラノシド又はその薬理上許容される塩若しくはエステルである請求項１乃至３２に記載の医薬組成物。 α-Amylase inhibitor is (2R, 3R, 4R) -4-hydroxy-2- (hydroxymethyl) pyrrolidin-3-yl 4-O- (6-deoxy-α-D-glucopyranosyl) -α-D-glucopyranoside , (2R, 3R, 4R) -4-hydroxy-2- (hydroxymethyl) pyrrolidin-3-yl 4-O- (6-deoxy-β-D-glucopyranosyl) -α-D-glucopyranoside or its pharmacologically acceptable The pharmaceutical composition according to any one of claims 1 to 32 , which is a salt or ester to be produced. α‐アミラーゼ阻害剤が (2R,3R,4R)-4-ヒドロキシ-2-(ヒドロキシメチル)ピロリジン-3-イル 4-O-(6-デオキシ-β-D-グルコピラノシル)-α-D-グルコピラノシド又はその薬理上許容される塩若しくはエステルである請求項１乃至３２に記載の医薬組成物。 α-Amylase inhibitor is (2R, 3R, 4R) -4-hydroxy-2- (hydroxymethyl) pyrrolidin-3-yl 4-O- (6-deoxy-β-D-glucopyranosyl) -α-D-glucopyranoside or a pharmaceutical composition according to claims 1 to 32 that is a pharmacologically acceptable salt or ester. α‐アミラーゼ阻害剤が (2R,3R,4R)-4-ヒドロキシ-2-(ヒドロキシメチル)ピロリジン-3-イル 4-O-(6-デオキシ-β-D-グルコピラノシル)-α-D-グルコピラノシドである請求項１乃至３２に記載の医薬組成物。α-Amylase inhibitor is (2R, 3R, 4R) -4-hydroxy-2- (hydroxymethyl) pyrrolidin-3-yl 4-O- (6-deoxy-β-D-glucopyranosyl) -α-D-glucopyranoside The pharmaceutical composition according to claim 1 to 32. α‐アミラーゼ阻害剤が (2R,3R,4R)-4-ヒドロキシ-2-(ヒドロキシメチル)ピロリジン-3-イル 4-O-(6-デオキシ-β-D-グルコピラノシル)-α-D-グルコピラノシドである請求項１乃至３３に記載の医薬組成物。α-Amylase inhibitor is (2R, 3R, 4R) -4-hydroxy-2- (hydroxymethyl) pyrrolidin-3-yl 4-O- (6-deoxy-β-D-glucopyranosyl) -α-D-glucopyranoside 34. The pharmaceutical composition according to claims 1-33. α‐アミラーゼ阻害剤が (2R,3R,4R)-4-ヒドロキシ-2-(ヒドロキシメチル)ピロリジン-3-イル 4-O-(6-デオキシ-β-D-グルコピラノシル)-α-D-グルコピラノシドであり、インスリン感受性増強剤がピオグリタゾンである、請求項１０乃至１３に記載の医薬組成物。α-Amylase inhibitor is (2R, 3R, 4R) -4-hydroxy-2- (hydroxymethyl) pyrrolidin-3-yl 4-O- (6-deoxy-β-D-glucopyranosyl) -α-D-glucopyranoside The pharmaceutical composition according to any one of claims 10 to 13, wherein the insulin sensitivity enhancer is pioglitazone. α‐アミラーゼ阻害剤が (2R,3R,4R)-4-ヒドロキシ-2-(ヒドロキシメチル)ピロリジン-3-イル 4-O-(6-デオキシ-β-D-グルコピラノシル)-α-D-グルコピラノシドであり、インスリン分泌促進剤がナテグリニドである、医薬組成物。α-Amylase inhibitor is (2R, 3R, 4R) -4-hydroxy-2- (hydroxymethyl) pyrrolidin-3-yl 4-O- (6-deoxy-β-D-glucopyranosyl) -α-D-glucopyranoside A pharmaceutical composition, wherein the insulin secretagogue is nateglinide. α‐アミラーゼ阻害剤が (2R,3R,4R)-4-ヒドロキシ-2-(ヒドロキシメチル)ピロリジン-3-イル 4-O-(6-デオキシ-β-D-グルコピラノシル)-α-D-グルコピラノシドであり、ビグアナイド剤がメトホルミンである、請求項２０乃至２２に記載の医薬組成物。α-Amylase inhibitor is (2R, 3R, 4R) -4-hydroxy-2- (hydroxymethyl) pyrrolidin-3-yl 4-O- (6-deoxy-β-D-glucopyranosyl) -α-D-glucopyranoside The pharmaceutical composition according to any one of claims 20 to 22, wherein the biguanide is metformin. α‐アミラーゼ阻害剤が (2R,3R,4R)-4-ヒドロキシ-2-(ヒドロキシメチル)ピロリジン-3-イル 4-O-(6-デオキシ-β-D-グルコピラノシル)-α-D-グルコピラノシドであり、DPP-IV阻害剤がMK-0431である、医薬組成物。α-Amylase inhibitor is (2R, 3R, 4R) -4-hydroxy-2- (hydroxymethyl) pyrrolidin-3-yl 4-O- (6-deoxy-β-D-glucopyranosyl) -α-D-glucopyranoside And the DPP-IV inhibitor is MK-0431. α‐アミラーゼ阻害剤が (2R,3R,4R)-4-ヒドロキシ-2-(ヒドロキシメチル)ピロリジン-3-イル 4-O-(6-デオキシ-β-D-グルコピラノシル)-α-D-グルコピラノシドであり、インスリン製剤が速効型インスリンである、医薬組成物。α-Amylase inhibitor is (2R, 3R, 4R) -4-hydroxy-2- (hydroxymethyl) pyrrolidin-3-yl 4-O- (6-deoxy-β-D-glucopyranosyl) -α-D-glucopyranoside A pharmaceutical composition, wherein the insulin preparation is fast-acting insulin. 糖尿病の予防及び治療薬である請求項１乃至４２に記載の医薬組成物。 43. The pharmaceutical composition according to claim 1 to 42 , which is a preventive and therapeutic agent for diabetes. 食後過血糖症の予防及び治療薬である請求項１乃至４２に記載の医薬組成物。 43. The pharmaceutical composition according to claims 1 to 42 , which is a preventive and therapeutic agent for postprandial hyperglycemia. 単独投与に比べて血糖低下作用の増強された糖尿病の予防及び治療用である、請求項１乃至４２に記載の医薬組成物。 The pharmaceutical composition according to any one of claims 1 to 42 , which is used for the prophylaxis and treatment of diabetes whose blood glucose lowering action is enhanced as compared with single administration. それぞれの薬剤を同時に又は時間をおいて相前後して投与するための、請求項１乃至４５に記載の医薬組成物。46. The pharmaceutical composition according to any one of claims 1 to 45, wherein each drug is administered simultaneously or in succession with time. 下記一般式(I)

[式中、Aは下記一般式(A1)、(A2)又は(A3)

を示し、R1及びR２はそれぞれ同一若しくは異なって、C1-6アルキル基、ヒドロキシメチル基、C1-6アルコキシメチル基又はC1-6ハロアルキル基を示し、R3、R4、R5及びR6はそれぞれ同一若しくは異なって、C1-6アルキル基、C1-6アルコキシ基、C1-6ヒドロキシアルキル基、C1-6ハロアルキル基、アミノ基(該アミノ基はC1-6アルキル基又はC1-6ヒドロキシアルキル基で1又は2個置換されていてもよい) 、水酸基、水素原子又はハロゲン原子を示し、R7はC1-6アルキル基、C1-6アルコキシ基、C1-6ヒドロキシアルキル基、C1-6ハロアルキル基、水酸基又は水素原子を示し、nは1又は2の整数を示す。] で表わされる化合物又はその薬理上許容される塩若しくはエステルから選ばれるα‐アミラーゼ阻害剤と、インスリン感受性増強剤、インスリン分泌促進剤、ビグアナイド剤、インスリン製剤及びDPP-IV阻害剤から選ばれる少なくとも一種の薬剤とを組み合わせてなる医薬組成物を製造するための、α‐アミラーゼ阻害剤と、インスリン感受性増強剤、インスリン分泌促進剤、ビグアナイド剤、インスリン製剤及びDPP-IV阻害剤から選ばれる薬剤の使用。 The following general formula (I)

[Wherein A represents the following general formula (A1), (A2) or (A3)

R 1 and R 2 are the same or different and each represents a C 1-6 alkyl group, a hydroxymethyl group, a C 1-6 alkoxymethyl group or a C 1-6 haloalkyl group, and R 3 , R 4 , R 5 and R 6 are the same or different and each represents a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 hydroxyalkyl group, a C1-6 haloalkyl group, an amino group (the amino group is a C1-6 alkyl group or a C1-6 hydroxy group). 1 or 2 may be substituted with an alkyl group), a hydroxyl group, a hydrogen atom or a halogen atom, R 7 is a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 hydroxyalkyl group, C1-6 A haloalkyl group, a hydroxyl group or a hydrogen atom; n represents an integer of 1 or 2; An α-amylase inhibitor selected from the compounds represented by the formula (I) or a pharmacologically acceptable salt or ester thereof, and at least selected from an insulin sensitivity enhancer, an insulin secretagogue, a biguanide, an insulin preparation, and a DPP-IV inhibitor. An α-amylase inhibitor and an agent selected from an insulin sensitivity enhancer, an insulin secretagogue, a biguanide, an insulin preparation and a DPP-IV inhibitor for producing a pharmaceutical composition comprising a combination of one kind of drug use. α‐アミラーゼ阻害剤が(2R,3R,4R)-4-ヒドロキシ-2-(ヒドロキシメチル)ピロリジン-3-イル 4-O-(6-デオキシ-α-D-グルコピラノシル)-α-D-グルコピラノシドである請求項４７に記載の使用。α-Amylase inhibitor is (2R, 3R, 4R) -4-hydroxy-2- (hydroxymethyl) pyrrolidin-3-yl 4-O- (6-deoxy-α-D-glucopyranosyl) -α-D-glucopyranoside 48. Use according to claim 47, wherein α‐アミラーゼ阻害剤が(2R,3R,4R)-4-ヒドロキシ-2-(ヒドロキシメチル)ピロリジン-3-イル 4-O-(6-デオキシ-β-D-グルコピラノシル)-α-D-グルコピラノシドである請求項４７に記載の使用。α-Amylase inhibitor is (2R, 3R, 4R) -4-hydroxy-2- (hydroxymethyl) pyrrolidin-3-yl 4-O- (6-deoxy-β-D-glucopyranosyl) -α-D-glucopyranoside 48. Use according to claim 47, wherein
JP2005219763A 2004-07-29 2005-07-29 Medicinal composition containing diabetes therapeutic agent Pending JP2006063074A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005219763A JP2006063074A (en) 2004-07-29 2005-07-29 Medicinal composition containing diabetes therapeutic agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004222419 2004-07-29
JP2005219763A JP2006063074A (en) 2004-07-29 2005-07-29 Medicinal composition containing diabetes therapeutic agent

Publications (2)

Publication Number Publication Date
JP2006063074A JP2006063074A (en) 2006-03-09
JP2006063074A5 true JP2006063074A5 (en) 2008-09-04

Family

ID=36109854

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005219763A Pending JP2006063074A (en) 2004-07-29 2005-07-29 Medicinal composition containing diabetes therapeutic agent

Country Status (1)

Country Link
JP (1) JP2006063074A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3017536B1 (en) * 2014-02-18 2017-05-26 Univ La Rochelle COMPOSITIONS FOR THE PREVENTION AND / OR TREATMENT OF ALPHA GLUCOSIDASE PATHOLOGIES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02215394A (en) * 1989-02-14 1990-08-28 Nippon Shinyaku Co Ltd Production of moranoline derivative
JP2000044589A (en) * 1998-08-03 2000-02-15 Kikkoman Corp Maltooligosaccharide derivative and its use
JP3909735B2 (en) * 1999-02-22 2007-04-25 キッコーマン株式会社 Maltooligosaccharide derivatives and uses thereof
JP4373671B2 (en) * 2000-06-06 2009-11-25 キッコーマン株式会社 Maltooligosaccharide derivatives and uses thereof

Similar Documents

Publication Publication Date Title
KR101345316B1 (en) Dipeptidyl peptidase inhibitors for treating diabetes
KR101352588B1 (en) Dipeptidyl peptidase inhibitors for treating diabetis
US20200046713A1 (en) Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
CA2724133C (en) Medicine consisting of concomitant use or combination of dpp-iv inhibitor and other diabetic medicine
CN109700814A (en) The treatment of diabetes pair although using oral or non-oral antidiabetic medicine treatment in the still insufficient patient of glycemic control
US20040209891A1 (en) Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV
CN102971005A (en) Diabetes therapy
JP2010530431A5 (en)
KR20150032590A (en) Use of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile
CN102946875A (en) Combination therapy
JP2016518438A (en) Combination of DPP-4 inhibitor and α-glucosidase inhibitor
KR20150038706A (en) Weekly administration of dipeptidyl peptidase inhibitors
JP2020529440A5 (en)
CA2575521A1 (en) Medicinal composition containing diabetes remedy
JPWO2007007757A1 (en) Pharmaceutical composition containing a PPARγ agonist
JP2006063074A5 (en)
WO2009128360A1 (en) Therapeutic agent for diabetes
WO2011002011A1 (en) Combined medicine of sglt1 inhibitor and dpp-iv inhibitor
TWI842924B (en) Pharmaceutical combination and pharmaceutical kit of gpr119 agonists and dpp-4 inhibitors
RU2818562C2 (en) Combined therapy with gpr119 agonists and dpp-4 inhibitors
JP4433496B2 (en) Pharmaceutical composition for suppressing expression of ATP citrate lyase and use thereof
JP2009513593A (en) Diabetes treatment
WO2015134357A1 (en) Modulators of insulin receptor
JP2002173426A (en) Hypoglycemic agent
CN1592620A (en) Treating and preventing method of disease relative to cardiac insulin resistance